Bristol Myers' TYK2 drug bombs ulcerative colitis test, but hopes are still high with psoriasis filing on deck
Bristol Myers Squibb’s deucravacitinib, seeking to become the first TYK2 drug approved, flopped a key Phase II test in ulcerative colitis, failing to spur clinical remission at three months and missing key secondary endpoints at an interim check-in, the drug giant admitted Thursday.
Details were slim in a press release, but Bristol Myers noted it still has plans to pursue deucravacitinib in ulcerative colitis — another Phase II test is currently ongoing — as well as a host of other indications for what it still sees as a $4 billion-per-year peak seller by the end of the decade.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.